Search

Treatment of indenyl-modified imidazolium bromide C9H7CH2CH2(NCHCHN(C6H2Me3-2,4,6)CH)Br ((IndH-NHC-H)Br) with rare earth metal tetra(alkyl) lithium (Ln(CH2SiMe3)4Li(THF)4) or with (trimethylsilylmethyl)lithium (LiCH2SiMe3) and rare earth metal tris(alkyl)s (Ln(CH2SiMe3)3(THF)2) sequentially afforded the first NHC-stabilized monomeric rare earth metal bis(alkyl) complexes (Ind-NHC)Ln(CH2SiMe3)2(1, Ln Y; 2, Ln Lu; 3, Ln Sc) via double-deprotonation reactions. Complexes 1−3are THF-free isostructural monomers. The monoanionic Ind-NHC species bond to the central metal ion in a 5:1constrained geometry configuration (CGC) mode, which combine with the two cis-located alkyl moieties to form a tetrahedron ligand core, leading to the chirality of the complexes. Under the presence of activators AlEt3and Ph3CB(C6F5)4, complex 2showed catalytic activity toward the polymerization of isoprene to afford 3,4-regulated polyisoprene (91%). [ABSTRACT FROM AUTHOR]

We report herein a new class of small-molecule inhibitors of antiapoptotic Bcl-2 proteins. The most potent compound, 7, binds to Bcl-2, Bcl-xL, and Mcl-1 proteins with Kiof 110, 638, and 150 nM, respectively. Compound 7is highly effective in induction of cell death in breast cancer cells with high levels of Bcl-2, Bcl-xL, and Mcl-1 proteins and represents a promising lead compound for the design of new anticancer drugs. [ABSTRACT FROM AUTHOR]

This article presents a structure-based design of potent non-peptide MDM2 oncoprotein inhibitors. It is believed that the p53 tumor suppressor plays a central role in controlling cell cycle progression and apoptosis, and is an attractive cancer therapeutic target because its tumor suppressor activity can be stimulated to eradicate tumor cells. A new approach to stimulation of the activity of p53 is through blocking its interaction with the MDM2 oncoprotein, an endogenous cellular inhibitor of p53, using non-peptide small-molecule MDM2 inhibitors.